Class information for:
Level 1: PHENYLACETATE//ANTINEOPLASTON AS2 1//PHENYLBUTYRATE

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
27711 223 29.7 70%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
5 4 CHEMISTRY, ORGANIC//CHEMISTRY, INORGANIC & NUCLEAR//CHEMISTRY, MULTIDISCIPLINARY 1745167
346 3       CARDIOTOXICITY//ANTHRACYCLINES//CAMPTOTHECIN 36072
3321 2             BLEOMYCIN//MIGRASTATIN//BLEOMYCIN HYDROLASE 1808
27711 1                   PHENYLACETATE//ANTINEOPLASTON AS2 1//PHENYLBUTYRATE 223

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 PHENYLACETATE authKW 958482 9% 33% 21
2 ANTINEOPLASTON AS2 1 authKW 684650 2% 100% 5
3 PHENYLBUTYRATE authKW 625689 9% 24% 19
4 ANTINEOPLASTON A10 authKW 570540 2% 83% 5
5 SODIUM PHENYLACETATE NAPA authKW 410790 1% 100% 3
6 EQUIPE ONCOL CELLULAIRE MOL address 273860 1% 100% 2
7 SODIUM PHENYLACETATE authKW 199166 2% 36% 4
8 ANTINEOPLASTONS authKW 182572 1% 67% 2
9 AROMATIC FATTY ACIDS authKW 182572 1% 67% 2
10 PHENYLACETATE DERIVATIVE authKW 182572 1% 67% 2

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Oncology 1557 43% 0% 97
2 Pharmacology & Pharmacy 525 30% 0% 66
3 Integrative & Complementary Medicine 137 3% 0% 7
4 Chemistry, Medicinal 45 5% 0% 11
5 Urology & Nephrology 10 3% 0% 6
6 Medicine, Research & Experimental 9 4% 0% 8
7 Hematology 8 3% 0% 6
8 Medicine, General & Internal 8 4% 0% 10
9 Biology 3 2% 0% 4
10 Geriatrics & Gerontology 3 1% 0% 2

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 EQUIPE ONCOL CELLULAIRE MOL 273860 1% 100% 2
2 CHIM BIOL BIOMAT 136930 0% 100% 1
3 CIBLAGE FONCT TUMEURS SOLIDESSMBII 136930 0% 100% 1
4 CNRS URM 502 136930 0% 100% 1
5 EQUIPE ONCOL 136930 0% 100% 1
6 INTE UNIV HEMATOL 136930 0% 100% 1
7 NEUROCHIRURG KLIN FN 136930 0% 100% 1
8 NEW PROACHES BRAIN TUMOR THER Y CNS CONSORTIUM 136930 0% 100% 1
9 ONCOL CELLULAIRE MOL EA 2360 136930 0% 100% 1
10 ONCOL CELLULAIRE MOL HUMAINE 136930 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH 71455 14% 2% 31
2 AMERICAN JOURNAL OF CHINESE MEDICINE 2387 3% 0% 6
3 CLINICAL CANCER RESEARCH 1317 5% 0% 12
4 CANCER RESEARCH THERAPY & CONTROL 1051 0% 1% 1
5 ANTICANCER RESEARCH 1019 5% 0% 12
6 CANCER LETTERS 715 4% 0% 8
7 ANTI-CANCER DRUGS 665 2% 0% 4
8 CANCER CHEMOTHERAPY AND PHARMACOLOGY 663 3% 0% 6
9 ONCOLOGY REPORTS 489 3% 0% 6
10 INTERNATIONAL JOURNAL OF ONCOLOGY 224 2% 0% 4

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 PHENYLACETATE 958482 9% 33% 21 Search PHENYLACETATE Search PHENYLACETATE
2 ANTINEOPLASTON AS2 1 684650 2% 100% 5 Search ANTINEOPLASTON+AS2+1 Search ANTINEOPLASTON+AS2+1
3 PHENYLBUTYRATE 625689 9% 24% 19 Search PHENYLBUTYRATE Search PHENYLBUTYRATE
4 ANTINEOPLASTON A10 570540 2% 83% 5 Search ANTINEOPLASTON+A10 Search ANTINEOPLASTON+A10
5 SODIUM PHENYLACETATE NAPA 410790 1% 100% 3 Search SODIUM+PHENYLACETATE+NAPA Search SODIUM+PHENYLACETATE+NAPA
6 SODIUM PHENYLACETATE 199166 2% 36% 4 Search SODIUM+PHENYLACETATE Search SODIUM+PHENYLACETATE
7 ANTINEOPLASTONS 182572 1% 67% 2 Search ANTINEOPLASTONS Search ANTINEOPLASTONS
8 AROMATIC FATTY ACIDS 182572 1% 67% 2 Search AROMATIC+FATTY+ACIDS Search AROMATIC+FATTY+ACIDS
9 PHENYLACETATE DERIVATIVE 182572 1% 67% 2 Search PHENYLACETATE+DERIVATIVE Search PHENYLACETATE+DERIVATIVE
10 CDA II 146053 2% 27% 4 Search CDA+II Search CDA+II

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 CAMACHO, LH , OLSON, J , TONG, WP , YOUNG, CW , SPRIGGS, DR , MALKIN, MG , (2007) PHASE I DOSE ESCALATION CLINICAL TRIAL OF PHENYLBUTYRATE SODIUM ADMINISTERED TWICE DAILY TO PATIENTS WITH ADVANCED SOLID TUMORS.INVESTIGATIONAL NEW DRUGS. VOL. 25. ISSUE 2. P. 131-138 21 53% 45
2 BERG, S , SERABE, B , ALEKSIC, A , BOMGAARS, L , MCGUFFEY, L , DAUSER, R , DURFEE, J , NUCHTERN, J , BLANEY, S , (2001) PHARMACOKINETICS AND CEREBROSPINAL FLUID PENETRATION OF PHENYLACETATE AND PHENYLBUTYRATE IN THE NONHUMAN PRIMATE.CANCER CHEMOTHERAPY AND PHARMACOLOGY. VOL. 47. ISSUE 5. P. 385-390 18 75% 26
3 FRANK, L , AVRAMOGLOU, T , SAINTE-CATHERINE, O , JOZEFONVICZ, J , KRAEMER, M , (2004) GROWTH INHIBITION OF MCF-7 TUMOR CELL LINE BY PHENYLACETATE LINKED TO FUNCTIONALIZED DEXTRAN.JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION. VOL. 15. ISSUE 10. P. 1305-1315 17 74% 0
4 LI, XN , PARIKH, S , SHU, Q , JUNG, HL , CHOW, CW , PERLAKY, L , LEUNG, HCE , SU, J , BLANEY, S , LAU, CC , (2004) PHENYLBUTYRATE AND PHENYLACETATE INDUCE DIFFERENTIATION AND INHIBIT PROLIFERATION OF HUMAN MEDULLOBLASTOMA CELLS.CLINICAL CANCER RESEARCH. VOL. 10. ISSUE 3. P. 1150-1159 23 51% 41
5 CHANG, SM , KUHN, JG , ROBINS, HI , SCHOLD, SC , SPENCE, AM , BERGER, MS , MEHTA, MP , BOZIK, ME , POLLACK, I , SCHIFF, D , ET AL (1999) PHASE II STUDY OF PHENYLACETATE IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA: A NORTH AMERICAN BRAIN TUMOR CONSORTIUM REPORT.JOURNAL OF CLINICAL ONCOLOGY. VOL. 17. ISSUE 3. P. 984-990 17 71% 53
6 ENDO, Y , WATANABE, N , SUGANO, S , WATANABE, M , MIYAJIMA, N , IGARASHI, M , (2009) SODIUM PHENYLACETATE INHIBITS THE RAS/MAPK SIGNALING PATHWAY TO INDUCE REDUCTION OF THE C-RAF-1 PROTEIN IN HUMAN AND CANINE BREAST CANCER CELLS.BREAST CANCER RESEARCH AND TREATMENT. VOL. 118. ISSUE 2. P. 281 -291 19 46% 1
7 BURZYNSKI, SR , (1995) POTENTIAL OF ANTINEOPLASTONS IN DISEASES OF OLD-AGE.DRUGS & AGING. VOL. 7. ISSUE 3. P. 157-167 36 38% 4
8 THOMPSON, P , BALIS, F , SERABE, BM , BERG, S , ADAMSON, P , KLENKE, R , AIKEN, A , PACKER, R , MURRY, DJ , JAKACKI, R , ET AL (2003) PHARMACOKINETICS OF PHENYLACETATE ADMINISTERED AS A 30-MIN INFUSION IN CHILDREN WITH REFRACTORY CANCER.CANCER CHEMOTHERAPY AND PHARMACOLOGY. VOL. 52. ISSUE 5. P. 417 -423 11 92% 5
9 FERRANDINA, G , MELICHAR, B , LOERCHER, A , VERSCHRAEGEN, CF , KUDELKA, AP , EDWARDS, CL , SCAMBIA, G , KAVANAGH, JJ , ABBRUZZESE, JL , FREEDMAN, RS , (1997) GROWTH INHIBITORY EFFECTS OF SODIUM PHENYLACETATE (NSC 3039) ON OVARIAN CARCINOMA CELLS IN VITRO.CANCER RESEARCH. VOL. 57. ISSUE 19. P. 4309-4315 18 64% 24
10 BUCKNER, JC , MALKIN, MG , REED, E , CASCINO, TL , REID, JM , AMES, MM , TONG, WPY , LIM, S , FIGG, WD , (1999) PHASE II STUDY OF ANTINEOPLASTONS A10 (NSC 648539) AND AS2-1 (NSC 620261) IN PATIENTS WITH RECURRENT GLIOMA.MAYO CLINIC PROCEEDINGS. VOL. 74. ISSUE 2. P. 137-145 14 78% 10

Classes with closest relation at Level 1


Rank Class id link
1 26139 RGTA//DERIVATIZED DEXTRANS//DEXTRAN DERIVATIVES
2 29693 BLEOMYCIN AMPLIFICATION//DNA DOCKING//2 5 DIARYLPYRIMIDINE
3 27406 MIGRASTATIN//CYCLOHEXYLAMINOGLUTETHIMIDE//GLUTARIMIDE
4 7109 BUTYRATE//SODIUM BUTYRATE//DIVERSION COLITIS
5 185 HISTONE DEACETYLASE INHIBITOR//HISTONE DEACETYLASE//HDAC INHIBITOR
6 4786 ORNITHINE TRANSCARBAMYLASE DEFICIENCY//HYPERAMMONEMIA//UREA CYCLE DISORDERS
7 32633 THIOSENS//PHARMACOL CELLULAIRE MOL ANTICANC//ALPHANIZOMENON FLOS AQUAE
8 24016 MEVALONATE DIPHOSPHATE DECARBOXYLASE//MEVALONATE PYROPHOSPHATE DECARBOXYLASE//MEVALONATE KINASE
9 14592 AMINOPEPTIDASE N//CD13//BESTATIN
10 9383 FETAL HEMOGLOBIN//HEMOGLOBINOPATHY THALASSEMIA UNIT//GAMMA GLOBIN

Go to start page